bioAffinity Technologies (NASDAQ: BIAF): Detecting Early-Stage Lung Cancer with CyPath Lung
Dec. 21, 2023
bioAffinity Technologies, Inc. (NASDAQ: BIAF) addresses the urgent need for noninvasive, early-stage cancer diagnosis and targeted cancer treatment. Its first product, CyPath® Lung, accurately diagnoses early-stage lung cancer, the leading cause of cancer-related deaths, by analyzing the lung microenvironment to characterize cell populations that are indicative of lung cancer. Physicians order CyPath® Lung for their patients at high risk for lung cancer after low-dose computed tomography (LDCT) reveals a suspicious finding. CyPath® Lung can dramatically increase overall diagnostic accuracy for lung cancer, leading to increased survival, fewer unnecessary invasive procedures, reduced patient anxiety and lower medical costs. To learn more visit: https://bit.ly/49vYFJr
